NDAORALTABLET
Approved
Nov 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEMIXYS is a fixed-dose combination oral tablet containing lamivudine and tenofovir disoproxil fumarate, two nucleoside reverse transcriptase inhibitors (NRTIs) used in HIV treatment. This combination targets HIV by inhibiting viral reverse transcriptase, preventing viral replication in infected patients. The product is indicated for HIV-1 infection management as part of combination antiretroviral therapy.
Peak
Product is in peak revenue phase with moderate competitive pressure (30/100), indicating stable commercial operations and established market presence.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TEMIXYS offers opportunity to manage a peak-lifecycle antiviral product in a stable, mature market with established patient populations. Career growth centers on defending market share, optimizing payer relationships, and supporting compliance-heavy medical affairs functions typical of HIV therapy portfolios.
Brand ManagerMedical Science Liaison
Worked on TEMIXYS at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.